LIXTE Biotechnology Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Details Narrative)

Stock-Based Compensation (Details Narrative) - USD ($)								3 Months Ended		6 Months Ended		12 Months Ended
Stock-Based Compensation (Details Narrative) - USD ($)	Jan. 28, 2015	Oct. 07, 2014	Jun. 26, 2014	Jan. 28, 2014	Dec. 24, 2013	Sep. 16, 2012	Jun. 20, 2007	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Apr. 07, 2015
Options exercisable period										2 years 7 months 13 days
Options, exercisable price per share								$ 0.564		$ 0.564		$ 0.626
Fair value of warrants									$ 224,074	$ 34,016	$ 302,691
Net loss								$ (500,651)	(741,326)	(1,458,570)	(1,670,141)
Operations for the aggregate fair value of these securities								76,750		76,750
Stock based compensation								$ 84,643	176,130	168,637	559,296
Total deferred compensation expense for outstanding value of unvested stock options										$ 20,000
Outstanding options to acquire common stock non-vested								150,000		150,000
Fair market value, per share										$ 0.26		$ 0.24
Intrinsic value of exercisable but unexercised in-the-money stock options										$ 16,500		$ 2,750
ProActive Capital Resources Group LLC [Member]
Options granted to purchase common stock		125,000
Number of option available for issuance		250,000
Options exercisable period		1 year
Options vest		125,000											125,000
Stock price per share		$ 0.066
Charges to operations		$ 45,500
Services cost		$ 1,500
Issuance of warrants to purchase of common stock		500,000
Fair value of warrants		$ 33,000
Fair value of common stock grants		$ 12,500
Andrew Robell [Member]
Options granted to purchase common stock		200,000
Options exercisable period		5 years
Options, fair value		$ 20,000
Francis Johnson [Member] \| Chem-Master International, Inc [Member]
Options exercisable period			5 years
Options, exercisable price per share			$ 0.25
Options vest			500,000
Options, fair value			$ 118,650
Stock price per share			$ 0.24
Dr. Kathleen P. Mullinix [Member]
Options granted to purchase common stock						200,000
Options exercisable period						5 years
Options, exercisable price per share						$ 0.65
Options, fair value						$ 118,000
Stock price per share						$ 0.59
Charges to operations									12,280		26,899
Andrew Robell [Member]
Options, exercisable price per share		$ 0.50
Options vest		100,000
Stock price per share		$ 0.10
Andrew Robell [Member] \| October 7, 2015 [Member]
Options vest		100,000
Consulting Arrangements [Member]
Charges to operations								$ 0	44,279	74,901	410,288
Consulting Arrangements [Member]
Options granted to purchase common stock				4,000,000
Options exercisable period				5 years
Options, exercisable price per share				$ 0.50
Options vest	2,000,000			2,000,000
Options, fair value				$ 596,400
Stock price per share				$ 0.15
Charges to operations				$ 298,200
Options, vesting date	Jan. 28, 2015
NDA Agreement [Member]
Options granted to purchase common stock					100,000
Options exercisable period					5 years
Options, exercisable price per share					$ 0.13
Options, fair value					$ 12,960
Stock price per share					$ 0.13
Charges to operations								$ 1,554	921	$ 3,870	3,459
Advisory Agreement [Member]
Charges to operations									$ 6,339		$ 13,116
2007 Stock Compensation Plan [Member]
Number of restricted stock issued							2,500,000
Options granted to purchase common stock										650,000
Number of option available for issuance								1,850,000		1,850,000
Immediate Vesting [Member] \| Dr. Kathleen P. Mullinix [Member]
Options vest						25,000
Immediate Vesting [Member] \| NDA Agreement [Member]
Options vest					25,000
Quarterly Vesting Thereafter [Member] \| Dr. Kathleen P. Mullinix [Member]
Options vest						25,000
Vesting On June 24, 2016 [Member] \| NDA Agreement [Member]
Options vest					25,000
Vesting On June 24, 2017 [Member] \| NDA Agreement [Member]
Options vest					25,000
Vested [Member] \| Andrew Robell [Member]
Options, fair value		$ 10,000